trial · primary record
Anifrolumab + APFS
Systemic Lupus Erythematosus
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 24 |
| Primary completion | 2031-09-05 |
| Primary endpoint | Maximum observed serum (peak) concentration (Cmax) |
| Registry ID | NCT07630714 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:49.099Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07630714
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.